Imaging of Head and Neck Skin Cancer

  • Komal Shah
  • Jane Onufer
  • Deborah F. MacFarlane


It is important for clinicians to understand and to take advantage of new imaging techniques available for the management of skin cancers. There is little written in either skin cancer or radiology texts on the topic of imaging in head and neck skin cancers. This chapter is an attempt to find a common ground between the disciplines of surgery and radiology so that each may communicate more effectively with the other, thereby benefiting patient care and health-care costs.


Computerize Tomography Sentinel Lymph Node Sentinel Lymph Node Biopsy Skin Cancer Neck Dissection 


  1. 1.
    Beckmann EC. CT scanning the early days. Br J Radiol. 2006;79:5–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007;188(2):586–592.CrossRefPubMedGoogle Scholar
  3. 3.
    U.S. Food and Drug Administration. Public health advisory and information for health care professionals: gadolinium-containing contrast agents for magnetic resonance imaging (marketed as Magnevist, Multihance, Omniscan, OptiMARK, Prohance). Accessed December 15, 2008.
  4. 4.
    Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001–2007. Accessed December 15, 2008.
  5. 5.
    Shellock FG. Pocket Guide to MR Procedures and Metallic Objects: Update 2001. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.Google Scholar
  6. 6.
    Nazarian S, Roguin A, Zviman MM, et al. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. Circulation. 2006;114(12):1232–1233.CrossRefGoogle Scholar
  7. 7.
    Parker GD, Harnsberger HR. Clinical-radiologic issues in perineural tumor spread of malignant diseases of the extracranial head and neck. Radiographics. 1991;11(3):383–399.Google Scholar
  8. 8.
    De Bondt RB, Nelemans PJ, Hofman PA, et al. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing ultrasound, ultrasound-guided fine needle aspiration, CT and MR imaging. Eur J Radiol. 2007;64(2):266–272.CrossRefPubMedGoogle Scholar
  9. 9.
    Branstetter BF, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT, Raman S, Meltzer CC. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005;235(2):580–586.CrossRefPubMedGoogle Scholar
  10. 10.
    Fletcher J, Djulbegovic B, Soares H, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480–508.CrossRefPubMedGoogle Scholar
  11. 11.
    Even-Sapir E, Lerman H, Lievshitz G, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med. 2003;44(9):1413–1420.PubMedGoogle Scholar
  12. 12.
    Kienstra M, Padhya T. Head and neck melanoma. Cancer Control. 2005;12(4):242–247.PubMedGoogle Scholar
  13. 13.
    Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112(4):717–723.CrossRefPubMedGoogle Scholar
  14. 14.
    Adams S, Baum R, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25(9):1255–1260.CrossRefPubMedGoogle Scholar
  15. 15.
    Wagner J, Evdokimow D, Weisberger E, et al. Sentinel node biopsy for high-risk nonmelanoma cutaneous malignancy. Arch Dermatol. 2004;140:75–79.CrossRefPubMedGoogle Scholar
  16. 16.
    Huang CL, Halpern AC. Management of the patient with melanoma. In: Rigel D, ed. Cancer of the Skin. Philadelphia, PA: Elsevier Saunders; 2005:265.Google Scholar
  17. 17.
    Pathak I, O’Brien CJ, Petersen-Schaeffer K, et al. Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck. 2001;23(9):785–790.CrossRefPubMedGoogle Scholar
  18. 18.
    Kransdorf MJ, Meis-Kindblom JM. Dermatofibrosarcoma protuberans: Radiologic appearance. Am J Roentgenol. 1994;163(2):391–394.Google Scholar
  19. 19.
    Torreggiani W, Al-Ismail K, Munk P, Nicolaou S, O’Connell J, Knowling M. Dermatofibrosarcoma protuberans: MR imaging features. Am J Roentgenol. 2002;178:989–993.Google Scholar
  20. 20.
    Thornton S, Reid J, Papay F, Vidimos A. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol. 2005;53(1):76–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001;8(3):204–208.CrossRefPubMedGoogle Scholar
  22. 22.
    Gupta SG, Wang LC, Peñas PF, Gellenthin M, Lee SJ, Nghiem P. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: the Dana-Farber experience and review of the literature. Arch Dermatol. 2006;142: 685–690.CrossRefPubMedGoogle Scholar
  23. 23.
    Yao M, Smith R, Hoffman H, Funk G, Graham M, Buatti J. Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol. 2005;28(2):205–210.CrossRefPubMedGoogle Scholar
  24. 24.
    Belhocine T, Pierard G, Frühling J, et al. Clinical added-value of 19FDG PET in neuroendocrine-Merkel cell carcinoma. Oncol Rep. 2006;16:347–352.PubMedGoogle Scholar
  25. 25.
    Iagaru A, Quon A, McDougall IR, Gambhir SS. Merkel cell carcinoma: is there a role for 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography? Mol Imaging Biol. 2006;8:212–217.CrossRefPubMedGoogle Scholar
  26. 26.
    Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W. Clinical and laboratory investigations: somatostatin analogue scintigraphy in Merkel cell tumors. Br J Dermatol. 2003;148(6):1135–1140.CrossRefPubMedGoogle Scholar
  27. 27.
    Guitera-Rovel P, Lumbroso J, Gautier-Gougis M, et al. Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol. 2001;12:807–811.CrossRefPubMedGoogle Scholar
  28. 28.
    Shields J, Demirci H, Marr B, Eagle R, Shields C. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103–122.CrossRefPubMedGoogle Scholar
  29. 29.
    Saito A, Tsutsumida A, Furukawa H, Saito N, Yamamoto Y. Sebaceous carcinoma of the eyelids: a review of 21 cases. J Plast Reconstr Aesthet Surg. 2008;61(11):1328–1331.Google Scholar
  30. 30.
    Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008;47(3):276–279.CrossRefPubMedGoogle Scholar
  31. 31.
    Rosai J, Sumner HW, Kostianovsky M, Perez-Mesa C. Angiosarcoma of the skin: a clinicopathologic and fine structural study. Hum Pathol. 1976;7(1):83–109.CrossRefPubMedGoogle Scholar
  32. 32.
    Isoda H, Imai M, Inagawa S, Miura K, Sakahara H. Magnetic resonance imaging findings of angiosarcoma of the scalp. J Comput Assist Tomogr. 2005;29(6): 858–862.CrossRefPubMedGoogle Scholar
  33. 33.
    Hayman L, Shukla V, Ly D, Taber K. Clinical and imaging anatomy of the scalp. J Comput Assist Tomogr. 2003;27(3):454–459.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Komal Shah
    • 1
  • Jane Onufer
    • 2
  • Deborah F. MacFarlane
    • 3
  1. 1.Department of Diagnostic RadiologyM.D. Anderson Cancer Center, The University of TexasHoustonUSA
  2. 2.Department of Diagnostic RadiologyThe University of Texas, M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Departments of Dermatology and Plastic SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations